This joint resolution invokes chapter 8 of title 5 (the Congressional Review Act) to disapprove the Department of Veterans Affairs’ final rule titled “Reproductive Health Services” published at 90 Fed. Reg. 61310 (Dec. 31, 2025).
The single operative sentence declares that Congress disapproves that rule and that it "shall have no force or effect."
If enacted, the resolution would nullify the VA rule as though it had not legally taken effect and would trigger the CRA’s collateral consequence: the agency generally may not issue a new rule in substantially the same form without express statutory authorization. That consequence constrains the VA’s regulatory options and has immediate implications for veterans, VA providers, and the agency’s compliance and legal teams.
At a Glance
What It Does
The resolution disapproves a named VA final rule (90 Fed. Reg. 61310) under the Congressional Review Act and declares that the rule has no force or effect. By using the CRA vehicle, it also invokes the statute’s prohibition on reissuing substantially the same rule unless Congress later authorizes it.
Who It Affects
Directly affected parties include the Department of Veterans Affairs (rule authors and administrators), VA health-care providers and clinics, and veterans who would be covered or whose care would change under the rule. Federal rulemaking and regulatory affairs teams in other agencies will also note the precedent for CRA use.
Why It Matters
Disapproval does more than kill a single regulation — it limits the agency’s ability to return to the same regulatory text, forces administrative workarounds (guidance, statutory requests), and raises litigation risk over what counts as “substantially the same” in follow-up rulemakings. For health-care and compliance officers, it changes the baseline of obligations inside VA facilities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The resolution is short and targeted: it names the VA’s final rule on “Reproductive Health Services” (published at 90 Fed. Reg. 61310) and states that Congress disapproves it, rendering the rule without legal force.
Mechanically, the joint resolution is the statutory tool Congress uses under the Congressional Review Act (CRA) to nullify recently submitted agency rules.
Under the CRA framework the immediate effect of enactment would be to treat the identified rule as if it never took legal effect. That reverses any regulatory changes made by the rule, restores the prior regulatory baseline, and removes any legal rights or obligations created by the rule’s text.
The resolution itself does not replace the rule with alternative regulatory language nor does it amend the underlying statutes that govern VA authority.A consequential collateral effect of CRA disapproval is the prohibition on reissuing a rule that is “substantially the same” as the disapproved rule without subsequent congressional authorization. That restriction constrains the VA’s future rulemaking options: the agency can still change practice through other lawful means, but attempting to promulgate substantially similar regulatory text risks being invalidated again and invites litigation over the similarity standard.Practically, passage would force VA to unwind any policy or operational changes it implemented under the final rule.
That carries operational costs — revising clinical guidance, retraining staff, and updating benefit determinations — and creates program uncertainty for veterans whose care would have been affected. It also shifts the policy fight from rulemaking into Congress (for statutory change) or into agency guidance and interpretations (which themselves can be legally contested).
The Five Things You Need to Know
The resolution expressly disapproves the VA final rule titled “Reproductive Health Services,” published at 90 Fed. Reg. 61310 (Dec. 31, 2025).
It declares that the identified rule “shall have no force or effect,” meaning the regulation would be nullified if the resolution becomes law.
Because the resolution uses the Congressional Review Act, the VA is generally barred from issuing a new rule in substantially the same form unless Congress enacts a law authorizing it.
The resolution does not change the statutes that authorize VA action; it only removes the specific regulatory text and leaves open non-rule options (guidance, individual decisions) that the agency might deploy instead.
Nullifying the rule would require VA to revert to its prior regulatory baseline and would impose administrative burdens — updating policies, retraining clinicians, and revising beneficiary communications — for the agency and facilities.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Congressional disapproval language
This is the operative text: a single resolved clause that identifies the VA rule by title and Federal Register citation and states that Congress disapproves it. Practically, that clean, self-contained phrasing is designed to satisfy the statutory requirement for a CRA joint resolution — it targets one submitted rule rather than amending VA law. The clause’s phrasing (“shall have no force or effect”) is the standard effect language used in CRA disapprovals to nullify a final rule.
Precise rule identification
By citing the exact Federal Register entry (90 Fed. Reg. 61310, Dec. 31, 2025), the resolution limits its reach to that published final rule and avoids ambiguity about which agency action is disapproved. That precision matters because the CRA remedy attaches to particular rule submissions; an imprecise citation can produce disputes about whether follow-up or related guidance instruments fall within the resolution’s scope.
Collateral constraint on future rulemaking
Although the text does not restate CRA statutory mechanics, using chapter 8 of Title 5 imports them: once enacted, the CRA not only nullifies the rule but also bars the agency from issuing a substantially similar rule without new congressional authorization. For practitioners, that imported prohibition is the operative leverage: it changes the agency’s feasible pathways for implementing the same policy and raises the likelihood of litigation over any subsequent rulemaking that resembles the disapproved text.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Opponents of the VA rule: Individuals and organizations that opposed the regulatory change will see the status quo preserved and avoid any obligations or policy shifts the rule would have imposed.
- VA administrators tasked with compliance ease: Officials who must implement and oversee VA regulations avoid the short-term workload and compliance costs tied to adopting new regulatory procedures the rule would have required.
- Health systems and providers within VA that would have faced new mandates: Facilities that anticipated operational changes under the rule gain predictability by remaining under existing procedures.
Who Bears the Cost
- Veterans who would have benefited from the rule’s changes: If the rule expanded access to services, those potential beneficiaries lose the new regulatory entitlement unless Congress acts or the agency finds another lawful path.
- Department of Veterans Affairs (legal and regulatory teams): The agency incurs administrative and legal costs unwinding or pausing implementation, and it must assess alternative compliance options such as guidance or benefit directives.
- VA health-care providers and clinics: Even with the rule blocked, providers pay short-term costs from planning reversals, retraining, and updating operational protocols if implementation had already begun.
Key Issues
The Core Tension
The central dilemma is between legislative oversight and policy continuity: disapproval under the CRA is a powerful tool to check agency rules, but it can also abruptly withdraw regulatory protections or benefits and foreclose the agency from pursuing similar rules, forcing the policy debate back into a slower legislative or litigation channel without resolving the underlying statutory questions.
The core implementation question is not whether Congress can nullify a rule — it can — but what happens next. The CRA’s prohibition on reissuing a substantially similar rule is pivotal and legally ambiguous.
Courts frequently parse what “substantially the same” means by comparing text, effect, and underlying policy goals; agencies often try to redesign or reframe rules to avoid that bar, which invites litigation over semantic and functional differences. That litigation risk leaves agencies with three imperfect options: seek legislation to authorize the policy, issue narrower or differently structured rules that courts may nevertheless challenge, or attempt to change practice through nonrule guidance or internal directives that can prompt their own legal fights.
Another unresolved practical tension is severability and collateral effects. Nullifying a rule does not by itself rescind all administrative steps taken under it (contracts, discretionary determinations, or guidance issued to implement the rule).
Agencies will need to sort which operational changes must be rolled back and which persist — a process that consumes resources and creates legal ambiguity for veterans and providers. Finally, the resolution’s narrow form means it does not clarify underlying legal questions about VA authority to provide reproductive health services; it removes a regulatory text but leaves statutory interpretation and clinical policy debates to be resolved by VA, Congress, or the courts.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.